Entacapone, a catechol-O-methyltransferase inhibitor for treating Parkinson’s disease: review and current status

Bibliography

• DELWAIDE PJ, GONCE M: Pathophysiology of Parkin- son's signs. In: Parkinson's Disease and Movement Disor-ders. Jankovich J, Tolosa E (Eds.), Williams and Willkins, Baltimore, USA (1993):77–92.
   Google Scholar
• •The cardinal symptoms of Parkinson's disease and consid-erations for diagnosis.
   Google Scholar
• YOUNG AB, PENNEY J: Biochemical and functional or- ganization of the basal ganglia. In: Parkinson's Disease and Movement Disorders. Jankovich J, Tolosa E (Eds.), Wil-liams and Wilkins, Baltimore, USA (1993):1–12.
   Google Scholar
• •The proposed defective neuronal pathways within the basal ganglia in Parkinson's disease.
   Google Scholar
• BERNHEIMER H, BIRKMAYER W, HORNYKIEWICZ 0 et al.: Brain dopamine and syndromes of Parkinson and Huntington. Clinical morphological and neurochemi- cal correlations. J. Neurol. ScL (1973) 20:415–455.
   Google Scholar
• •Quantitation of the percent loss of dopaminergic neurones as a function of disease progression.
   Google Scholar
• TANNER CM, GOLDMAN SM: Epidemiology of Parkin- son's disease. Neurol. Clin. (1996) 14:317–335.
   PubMed Web of Science ®Google Scholar
• •Review of risk factors and demographical considerations.
   Google Scholar
• MITCHELL SL, KIELY SL, KIEL DP et al.: The epidemiol- ogy, clinical characteristics and natural history of older nursing home residents with a diagnosis of Park-inson's disease. J. Am. Geriatr. Soc. (1996) 44:394–399.
   PubMed Web of Science ®Google Scholar
• KOLLER W, VETERE-OVERFIELD B, GRAY C et al.: Envi-ronmental risk factors in Parkinson's disease. Neurol-ogy (1990) 40:1218–1221.
   PubMed Web of Science ®Google Scholar
• JENNER P, OLANOW CW: Oxidative stress and the pathogenesis of Parkinson's disease. Neurology (1996) 47 (Suppl. 3):5161–5170.
   Google Scholar
• •Review of evidence for oxidative stress and the role of MAO-B inhibition.
   Google Scholar
• HORNYKIEWICZ 0, KISH SJ: Biochemical pathophysiol- ogy of Parkinson's disease. In: Advances in Neurology. Yahr MD, Bergmann KF (Eds.), Raven Press, New York, USA (1986) :19–34.
   Google Scholar
• MANNISTO PT, ULMANEN I, LUNDSTROM K etal.: Charac-teristics of catechol-O-methyltransferase (COMT) and properties of selective COMT inhibitors. Prog. Drug Res. (1992) 39:291–350.
   Google Scholar
• OLANOW CW, KOLLER WC: An algorithm (decision tree) for the management of Parkinson's disease: treat-ment guidelines. Neurology (1998) 50 (Suppl. 3):S1–S55.
   Google Scholar
• ••A comprehensive consensus paper for the management ofthe symptoms and complications of Parkinson's disease.
   Google Scholar
• POEWE WH, WENNING GK: The natural history of Park- inson's disease. Neurology (1996) 47 (Suppl. 3) :S146–S152.
   Google Scholar
• •Evidence for decreased mortality as a consequence of levo-dopa therapy.
   Google Scholar
• CHASE TN: Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology (1998) 50\(Suppl. 5):S17–S25.
   Google Scholar
• CEDERBAUM JM, OLANOW CW: Aspects of levodopa pharmacokinetics and pharmacodynamics: bases of the modification of drug response during chronic treatment of Parkinson's disease. In: The Scientific Basis for the Treatment of Parkinson's disease. Olanow CW, Lie-berman AN (Eds.), The Parthenon Publishing Group, Park Ridge, NJ, USA (1992):113–135.
   Google Scholar
• HARDER S, BAAS H, RIETBROOK S: Concentration-effect relationship of levodopa in patients with Parkinson's disease. Clin. Pharmacokinet. (1995) 29:243–253.
   PubMed Web of Science ®Google Scholar
• •Proposed mechanisms for motor fluctuations due to long-term use of levodopa/carbidopa.
   Google Scholar
• SAGE JI, MARK MH: The rationale for continuous dopa- minergic stimulation in patients with Parkinson's dis-ease. Neurology (1992) 42 (Suppl. 0:23–28.
   Google Scholar
• •Rationale for the use of agents designed to enhance tonic stimulation of dopamine receptors.
   Google Scholar
• CHASE TN: The significance of continuous dopaminer- gic stimulation in the treatment of Parkinson's dis-ease. Drugs (1998) 55 (Suppl. 0:1–9.
   Google Scholar
• •The relative merits of tonic (continuous) versus phasic stimulation of dopamine receptors using long-acting dopa-mine agonists such as cabergoline and iv levodopa.
   Google Scholar
• LEWITT P: Treatment strategies for extension of levo-dopa effect. Neurologic Clinics (1992) 10:511–525.
   PubMed Web of Science ®Google Scholar
• GULDBERG HC, MARSDEN CA: Catechol-0-methyltransferase: pharmacological aspects and physiological role. Pharmacol. Rev. (1975) 27:135–206.
   PubMed Web of Science ®Google Scholar
• KAAKOLA S, GORDIN A, MANNISTO P: General proper-ties and clinical possibilities of new selective inhibi-tors of catechol-O-methyltransferase. Gen. Pharmacol. (1994) 25:813–824.
   PubMedGoogle Scholar
• •A comparison of the pharmacokinetic and pharmacody-namic properties of nitecapone, entacapone and tolcapone.
   Google Scholar
• BACKSTROM R, HONKANEN E, PIPPURI A et al: Synthesis of some novel potent and selective catechol-0-methyltransferase inhibitors. J. Med. Chem. (1989) 32:841–846.
   PubMed Web of Science ®Google Scholar
• •Preparation of catechol derivatives to evaluate the effect of various functional groups on inhibiting metabolic enzyme activity.
   Google Scholar
• NUTLEY NJ: Tasmar (tolcapone) package insert. Roche (1998).
   Google Scholar
• NUTT JG, WOODWARD WR, BECKNER RM et al.: Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurol. (1994) 44:913–919.
   PubMed Web of Science ®Google Scholar
• KERANEN T, GORDIN A, KARLSSON Metal: Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous admini-stration of entacapone. Eur. J. Pharmacol. (1994) 46:151–157.
   Web of Science ®Google Scholar
• •Pharmacokinetics and pharmacodynamics of entacapone in healthy volunteers over a range of doses.
   Google Scholar
• LYYTINEN J et al.: Simultaneous MAO-B and COMT inhi- bition in L-DOPA-treated patients with Parkinson's disease. Movement Disord. 1997 12(4):497–505.
   PubMed Web of Science ®Google Scholar
• •The extent of COMT inhibition from a specific dose of enta-capone in patients with Parkinson's disease.
   Google Scholar
• RUOTTINEN HM, RINNE UK.: A double-blind pharma-cokinetic and clinical dose-response study of entaca-pone as an adjuvant to levodopa in advanced Parkinson's disease. Clin. Neuropharmacol 19:283–296.
   Google Scholar
• RUOTTINEN HM, RINNE UK: Effect of one month's treat-ment with peripherally acting catechol-0-methyltransferase inhibitor, entacapone, on pharma-cokinetics and motor response to levodopa in ad-vanced parkinsonian patients. Clin. Neuropharmacol. (1996) 19:222–233.
   PubMed Web of Science ®Google Scholar
• MYLLYLA W, SOTANIEMI KA, ILLI A eta].: Effect of tolca-pone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur. J. Clin. Pharmacol (1993) 45:419-423. Evaluates the effect of entacapone on levodopa pharma-cokinetics in patients with Parkinson's disease. Also corre-lates pharmacokinetic changes with improved efficacy of levodopa.
   Google Scholar
• AHTILA S, KAAKOLA S, GORDIN A et al: Effect of entaca- pone, a COMT Inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa/carbidopa in volunteers. Neuropharmacol. (1995) 18:46–57.
   Web of Science ®Google Scholar
• •The effect of entacapone on the disposition of controlled-release levodopa/carbidopa in healthy volunteers.
   Google Scholar
• KAAKOLA S, TERAVAINEN H, AHTILA S et al: Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. Eur. J. Neu-rol. (1995) 2:341–347.
   PubMed Web of Science ®Google Scholar
• •Comparison of the effect of entacapone on the pharmacoki-netics of controlled release levodopa/ carbidopa versus the standard preparation in patients with Parkinson's disease.
   Google Scholar
• WIKBERG T, VUORELA A, OTTOILA P et al.: Identification of major metabolites of the catechol-0-methyltransferase inhibitor entacapone in rats and humans. Drug. Metab. Dispos. (1993) 21:81–92.
   PubMed Web of Science ®Google Scholar
• •Isolation of the products of entacapone metabolism.
   Google Scholar
• DELEU D, SARRE S, EBINGER G eta].: The effect of carbi-dopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in the beagle dog: an in vivo micro-dialysis study. J. Pharm. Exp. Ther. (1995) 273:1323–1331
   Google Scholar
• SAWLE GV, BURN DJ, MORRISH PK et al.: The effect of en-tacapone (OR-611) on brain 1181F-64,-fluorodopa me-tabolism: implications for levodopa therapy of Parkinson's disease. Neurology (1994) 44:1292–1297.
   PubMed Web of Science ®Google Scholar
• MERELLO M, LEES AJ, WEBSTER R eta].: Effect of entaca-pone, a peripherally acting levodopa in patients catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with Parkinson's disease. Neurol Neurosurg. Psychiat. (1994) 57:186–189.
   Google Scholar
• RINNE UK, LARSEN JP, SIDEN A et al.: Entacapone en-hances the response to levodopa in parkinsonian pa-tients with motor fluctuations. Neurology (1998) 51:1309–1314.
   PubMed Web of Science ®Google Scholar
• ••The safety and efficacy of entacapone compared to placeboin patients with motor fluctuations conducted in Scandinavia.
   Google Scholar
• PARKINSON STUDY GROUP: Entacapone improves mo- tor fluctuations in levodopa-treated Parkinson's dis-ease patients. Ann. Neurol (1997) 42:747–755.
   PubMed Web of Science ®Google Scholar
• ••The safety and efficacy of entacapone compared to placeboin patients with motor fluctuations conducted in North America.
   Google Scholar
• DATA ON FILE: Orion-Pharma Pharmaceuticals. Orion Corporation, Finland. Mildred D Gottwald University of California, Department of Clinical Pharmacy, San Francisco, California, USA Tel.: +1 415 502 5353; Fax: +1 415 476 6632; Email: [email protected]
   Google Scholar